Short answer
KalVista Pharmaceuticals, Inc. (KALV) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Chiesi agreed to acquire KalVista for $27.00 cash per share, making the transaction price the primary near-term valuation reference.
KalVista Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Chiesi agreed to acquire KalVista for $27.00 cash per share, making the transaction price the primary near-term valuation reference
- Tender offer launch due within 10 business days, expiring after 20 business days unless extended
- Closing requires more than 50% shareholder support plus U.S., German, and Italian regulatory clearances
- No financing condition, reducing funding-related closing risk
- $66.4 million termination fee payable by KalVista under specified circumstances, limiting competing-bid flexibility
Item 7.01 · Regulation FD Disclosure
- Boilerplate Reg FD disclaimer, not substantive business disclosure
- Exhibit information excluded from Exchange Act Section 18 liability
- No investor-actionable operating, financial, or strategic information in provided text
Item EX-99.1 · Exhibit EX-99.1
- Chiesi agreed to acquire KalVista for $27.00 per share in cash, valuing equity at approximately $1.9bn
- Offer represents a 36% premium to KalVista’s 30-day volume-weighted average price as of April 28, 2026
- Transaction transfers EKTERLY, the first oral on-demand HAE treatment, to Chiesi’s rare immunology portfolio
- EKTERLY generated $49M in 2025 sales after its US launch in July 2025
- Closing expected in Q3 2026, subject to majority tender participation and regulatory approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other KalVista Pharmaceuticals, Inc. 8-K filings
Get the next KALV 8-K as it lands
Follow KALV for push alerts, or ask the research agent what this filing means.